There are other stakeholders and customers in the health care system that prefer a net price-based model and don’t care about the difference between list and net or gross price and net price. And so for those, we have the lower net price product available. So just a reminder, we have a high list price at 5% below HUMIRA and then we have a low list price at 55% below HUMIRA. We also intend to ensure that AMGEVITA is an affordable medicine for patients by providing co-pay assistance as well as helping patients secure reimbursement through the insurer. We are also pleased to report that we enjoy broad access out of the gate on day 1 of launch with the 3 national pharmacy benefit managers, so broad parity coverage alongside HUMIRA.
Bob Bradway: Let me just — I note that we’re up to the half past the hour but we will continue to take questions for as long as necessary here to answer those questions and until there is a recording of this that will be available in the form of a transcript for those of you that have conflicts and can’t stay beyond the set time. So Arvind, why don’t you go to the next question?
Arvind Sood: Yes. The next question is from Colin Bristow for UBS. And here’s a question on the obesity pipeline. What update should we expect to get this year? Will we see data from the remaining 3 cohorts from the Phase I study? And then on AMG 786, when should we expect updates, more disclosure on this asset and program?
David Reese: Yes. In terms of the obesity pipeline, AMG 133, the 2 additional cohorts you’re referring to, I don’t know that we’ll see data over the course of this year on that. If that changes, of course, I’ll provide guidance. AMG 786 is a small molecule with a different mechanism of action, as indicated to GLP-1 or Gipper receptor agonist or antagonist. So that’s going through dose escalation over the course of the year. I’ll provide guidance in terms of when we may see data from that program. And of course, at the time of data availability, we’ll talk about the target as well.
Bob Bradway: Okay. Thanks, David. Arvind, let’s go to the next question.
Arvind Sood: So the next question is from Evan Seigerman from BMO Capital Markets. And Evan wanted to know, he said with slowing LUMAKRAS sales, can you expand on how you may have revised your commercial strategy to better align with the commercial potential of the assets?
Murdo Gordon: Yes. I’m not sure we have a slowing overall volume growth. I think what we saw and I mentioned this, it might not have come through clearly on the audio but in the quarter, we did see a price effect based on reaching reimbursement decision finalization in France. And so we had a $12 million charge in the quarter against LUMAKRAS. It grew 7% volume in the quarter. But I think we anticipated the opportunity for LUMAKRAS in second-line being limited to the incident population. And we are commercially and medically sized appropriately for that opportunity. I think as we expand into earlier lines of therapy or other tumor types, we will continue to invest behind the product.
Arvind Sood: Okay. The next question is from Michael Yee. And Michael wants to know, he said, on 2023 guidance, can you clarify what the input is for revenue growth versus EPS growth range? Specifically, is there a positive impact from BeiGene accounting? And does the tax rate of 18% to 19% negatively impact EPS? Or is COGS offset, as explained last year, is 2023 OpEx growing more than revenue?
